📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Wugen

1.1 - Company Overview

Wugen Logo

Wugen

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.

Products and services

  • WU-CART-007: An allogeneic CAR-T cell therapy targeting CD7 for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, engineered to prevent fratricide and reduce Graft vs. Host Disease risk
  • WU-NK-101: An allogeneic memory NK cell therapy for hematologic malignancies and solid tumors, developed to enhance anti-tumor responses and cytokine production to improve efficacy
  • Memory NK Platform: An off-the-shelf platform that generates memory NK cells without feeder cells, cryopreserved for use in cancer treatment

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Wugen

Accession Therapeutics Logo

Accession Therapeutics

HQ: United Kingdom Website
  • Description: Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Accession Therapeutics company profile →
ThromboDx Logo

ThromboDx

HQ: The Netherlands Website
  • Description: Provider of blood-based, platelet-powered molecular diagnostics, developed and commercialized through a proprietary technology platform that addresses the need for an easily accessible, minimally invasive source; with offices in Amsterdam, The Netherlands.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ThromboDx company profile →
Sesen Bio Logo

Sesen Bio

HQ: United States Website
  • Description: Provider of protein-based therapeutics focused on improving human health, including Vicineum, a locally administered targeted fusion protein for BCG-unresponsive non-muscle invasive bladder cancer, and VB6-845d, an anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sesen Bio company profile →
Quantum Surgical Logo

Quantum Surgical

HQ: France Website
  • Description: Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Quantum Surgical company profile →
Insure One Logo

Insure One

HQ: United States Website
  • Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Insure One company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Wugen

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Wugen

2.2 - Growth funds investing in similar companies to Wugen

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Wugen

4.2 - Public trading comparable groups for Wugen

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Wugen

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Wugen

What does Wugen do?

Wugen is a provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.

Who are Wugen's competitors?

Wugen's competitors and similar companies include Accession Therapeutics, ThromboDx, Sesen Bio, Quantum Surgical, and Insure One.

Where is Wugen headquartered?

Wugen is headquartered in United States.

How many employees does Wugen have?

Wugen has 1,000 employees 🔒.

When was Wugen founded?

Wugen was founded in 2010 🔒.

What sector and industry vertical is Wugen in?

Wugen is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Wugen

Who are the top strategic acquirers in Wugen's sector and industry

Top strategic M&A buyers and acquirers in Wugen's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Wugen?

Top strategic M&A buyers groups and sectors for Wugen include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Wugen's sector and industry vertical

Which are the top PE firms investing in Wugen's sector and industry vertical?

Top PE firms investing in Wugen's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Wugen's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Wugen's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Wugen's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Wugen include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Wugen's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Wugen?

The key public trading comparables and valuation benchmarks for Wugen include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Wugen for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Wugen with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Wugen's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Wugen with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Wugen's' sector and industry vertical?

Access recent funding rounds and capital raises in Wugen's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Wugen